TY  - JOUR
T1  - HIv, hepatitis drug interactions
AU  - Kuehn BM
Y1  - 2012/03/28
N1  - 10.1001/jama.2012.332
JO  - JAMA
SP  - 1243
EP  - 1243
VL  - 307
IS  - 12
N2  - 
Citing evidence from a pharmacokinetic study, the FDA warned that patients taking the hepatitis C–targeted protease inhibitor boceprevir along with any of the ritonavir-boosted HIV-targeting protease inhibitors atazanavir, darunavir, or lopinavir may have lower blood levels of 1 or both drugs. The label of boceprevir will be updated to indicate this potential interaction, and the drug's manufacturer has sent letters to warn physicians.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.332
UR  - http://dx.doi.org/10.1001/jama.2012.332
ER  -